Added to YB: 2026-09-14
Pitch date: 2026-09-11
BBOT [bullish]
BridgeBio Oncology Therapeutics, Inc.
Author Info
No bio for this author
Company Info
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Market Cap
$541.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.01
P/E
-1.16
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 3 Session 4 - BridgeBio Oncology Therapeutics, Inc.
BBOT (quick overview): BridgeBio Oncology Therapeutics is repositioning around three early RAS-pathway assets, led by BBO-8520 in second-line KRAS G12C lung cancer. Its combination with pembrolizumab produced a 75% response rate at 500 mg once daily in previously G12C-inhibitor-treated patients. At $5.69, upside could be substantial if durability and a registration path emerge, but the data remain early and potentially selected.
Read full article (2 min)